Navigation Links
Triptolide: A Potential Drug for Polycystic Kidney Disease

A treatment for polycystic kidney disease(PKD), a leading cause of fatal kidney failure worldwide, has been identified by a research// team led by Yale biochemist Craig Crews, according to a report in the Proceedings of the National Academy of Sciences.

Over 12 million people worldwide suffer from PKD, a genetic disorder that causes uncontrolled growth of cells lining tubules in the kidneys, and results in the formation of many, large fluid-filled cysts in the kidneys.

“Unfortunately, aside from kidney transplantation, there has been no cure for PKD, nor has there been a suitable drug treatment to slow its progression,” said Crews, associate professor of chemistry, molecular, cellular & developmental biology and pharmacology. “We hope that is about to change,” he said.

The mesh of Traditional Chinese Medicines (TCMs), current advances in chemistry and fundamental processes of developmental biology and health are a research focus for Crews. According to him, a roadblock in the path to TCMs as a source for new medical treatments is lack of understanding the biology and chemistry of how they work.

Triptolide is a potent, biologically active compound isolated from the medicinal ‘Thunder God Vine’ Tripterygium wilfordii Hook F. The TCM tea Lei Gong Teng made from this plant has been used for centuries, as a therapeutic against cancer, inflammation, and auto-immune diseases. Crews and colleagues showed that triptolide causes cell growth arrest in certain cell types.

Normal kidney tubule cells have a built in switch for regulating their growth — two proteins, PKD1 and PKD2, located on a bristle-like cilium that bends in response to fluid flow across the cell. During kidney development, cells destined to line a kidney tubule grow and divide until the tubule is formed, as sensed by fluid flow in the tubule. Fluid flow bends the primary cilium, giving a signal to stop cell growth. PKD is caused by a mutation in the P
'"/>




Page: 1 2

Related medicine news :

1. Potential New Cancer Gene Identified
2. Lack of Smell And Its Potential Risks
3. New Blood Thinner Pill - First Potential Alternative to Warfarin in 50 years
4. The Potential Of Cadaver Transplantation Programme In India
5. Another Potential Of Stem Cells Discovered: Used For Growing Cartilage
6. Yoga Guru Ramdev Invited to Tap Ayurveda Potential by Jharkhand Govt
7. A Protein In Yoghurt Has The Potential To Fight E. coli
8. Gold Therapy- A Potential Treatment For Autoimmune Diseases
9. Whirlpool Bath Tubs Contain Potentially Lethal Bacterial Strains
10. Potential Benefits Of New Nanotechnology
11. Hormone Can Foretell Presence Of Potentially Fatal Pulmonary Hypertension
Post Your Comments:
(Date:5/12/2008)...ay 12 /PRNewswire/ -- Fairbank Farms, a national,g... of selected ground beef,products produced at its ...opper, Shaw,s, BJ,s, and Wilson Farms retail outle...roduct may contain small pieces of hard plastic. A...of 05/13/08, 05/15/08, or a,"Julian date 124" on t...
(Date:5/12/2008)...umer sales increased 25% for the 12 weeks ended Ma...TSDALE, Ariz., May 12 /PRNewswire-FirstCall/ -- Ma...the-counter healthcare company,that develops and m...r ways,to get better(R)," today announced its fina...ar ended March 31, 2008., For the fourth quarter ...
(Date:5/12/2008)...ive prism glasses can significantly improve the vi...ia, a condition that blinds half the visual field ...were invented by Dr. Eli Peli, a Senior Scientist ... in the first community-based multi-center trial o...ue of the Archives of Ophthalmology. The study wa...
(Date:5/12/2008)...nts worldwide verify safety and quality of technic...terial., DENVER, May 12 /PRNewswire/ -- C5 Medica...or the medical device industry, has submitted a 51...Drug Administration (FDA) for,its new technical ce....,ZirDent(TM) is a zirconium material ideally suit...
Breaking Medicine News(10 mins):Health News:Fairbank Farms Issues Voluntary Recall for Selected Ground Beef Products 2Health News:Matrixx Initiatives, Inc. Announces Fiscal 2008 Revenue of $101 Million and Net Income Growth of 59% to $10.4 Million, or $1.04 Earnings Per Share Versus $0.66 in the Prior Year 2Health News:Matrixx Initiatives, Inc. Announces Fiscal 2008 Revenue of $101 Million and Net Income Growth of 59% to $10.4 Million, or $1.04 Earnings Per Share Versus $0.66 in the Prior Year 3Health News:Matrixx Initiatives, Inc. Announces Fiscal 2008 Revenue of $101 Million and Net Income Growth of 59% to $10.4 Million, or $1.04 Earnings Per Share Versus $0.66 in the Prior Year 4Health News:Matrixx Initiatives, Inc. Announces Fiscal 2008 Revenue of $101 Million and Net Income Growth of 59% to $10.4 Million, or $1.04 Earnings Per Share Versus $0.66 in the Prior Year 5Health News:Matrixx Initiatives, Inc. Announces Fiscal 2008 Revenue of $101 Million and Net Income Growth of 59% to $10.4 Million, or $1.04 Earnings Per Share Versus $0.66 in the Prior Year 6Health News:Matrixx Initiatives, Inc. Announces Fiscal 2008 Revenue of $101 Million and Net Income Growth of 59% to $10.4 Million, or $1.04 Earnings Per Share Versus $0.66 in the Prior Year 7Health News:Matrixx Initiatives, Inc. Announces Fiscal 2008 Revenue of $101 Million and Net Income Growth of 59% to $10.4 Million, or $1.04 Earnings Per Share Versus $0.66 in the Prior Year 8Health News:Prism glasses expand the view for patients with hemianopia 2Health News:Prism glasses expand the view for patients with hemianopia 3Health News:C5 Medical Werks Applies for Clearance, Certification and Licensing for the Global Marketing of ZirDent(TM) Ceramic CAD/CAM Dental Blocks 2
...he death of lives and turning the lives of people ...report submitted by Transparency International on ...ir findings in a report Global Corruption Report 2... care which has been hounded by corruption in all ...
...g with Boston Scientific to talk about the repairs...ng was held in 2001 with Schering-Plough // about ... But the company failed to make any amendments. Th...roval of Clarinex, a blockbuster allergy drug. ...
...n be treated with mouth devices which aid breathin...line treatment, according to // the guidelines whi...Sleep Medicine. Mouth Guards which are more common... recommended as initial treatment. The continuou...
... the Teratology Society published a paper in the j... Molecular Teratology. // In this paper they said...gnancy related complications and their babies deve... This paper talked in detail about the problems an...
Other Medicine News:Health News:Corruption and Fraud in Health Care system 2
(Date:5/12/2008)... May 12 /PRNewswire-USNewswire/ -- GlaxoSmithKline...onal Group (BIG), a leading,academic breast cancer...he,Spanish Breast Cancer Cooperative Group (SOLTI)...study that will examine the role of TYKERB(R) in t...oadjuvant Lapatinib and/or,Trastuzumab Treatment O...
(Date:5/9/2008)...ists will play key role in national effort probing...tion Education Specialist, Pennsylvania Game Comm... article are available from the,Game Commission,s ... on "Release,#049-08.", HARRISBURG, Pa., May 7 ...ommission has found itself on a new frontier: it i...
(Date:5/9/2008)...ay 9 /PRNewswire-USNewswire/ -- Osteoarthritis is ...hat affects almost 50,million people in the United...e in bone joints. The novel investigational pain m...gesic, provided significant relief,for patients wi...ith,placebo, and with fewer gastrointestinal side ...
(Date:5/9/2008)...dicine Studied in Patients Following Bunionectomy,...- Many foot-surgery,patients experience intense pa... one of the most common foot surgeries. The invest...ificant relief for patients who had this,surgery, ...with tapentadol,also resulted in patients reportin...
Breaking Medicine Technology:TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 2TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 3TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 4TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 5TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 6TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 7White Nose Syndrome: Is Pennsylvania Next? 2White Nose Syndrome: Is Pennsylvania Next? 3White Nose Syndrome: Is Pennsylvania Next? 4White Nose Syndrome: Is Pennsylvania Next? 5White Nose Syndrome: Is Pennsylvania Next? 6Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 2Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 3Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 4Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 5New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery 2New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery 3New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery 4New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery 5ANSYS Expands HPC Benchmarking Program 12413 1ANSYS Expands HPC Benchmarking Program 12413 2ANSYS Expands HPC Benchmarking Program 12413 3Former Biolase CEO 26 EVP Launch Technology4Medicine 12411 1Former Biolase CEO 26 EVP Launch Technology4Medicine 12411 2Federal Health IT Market to Reach 244 5 Billion by 2013 12409 1Federal Health IT Market to Reach 244 5 Billion by 2013 12409 2McGraw Hill Professional Products Win Awards From Association of American Publishers 12407 1McGraw Hill Professional Products Win Awards From Association of American Publishers 12407 2
...wire/ -- Southern,Research Institute, a not-for-pr...research in the areas of preclinical drug,discover...ientists,will be delivering one oral presentation ...ssociation for Cancer Research,(AACR) Annual Meeti...tal Roy of Southern Research will be presenting ne...
... NEWSWIRE) -- New data,presented at ECCMID highlig...s of Basilea,s (SWX:BSLN) two late-stage,drug cand...orted,both for ceftobiprole, the first anti-MRSA b...ent, and for isavuconazole, a,novel azole for the ...urther data on their respective breadths of spectr...
Other Medicine Technology:Southern Research Institute to Present at the 2007 American,Association For Cancer Research Annual Meeting 2Southern Research Institute to Present at the 2007 American,Association For Cancer Research Annual Meeting 3Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 2Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 3Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 4Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 5Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 6Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 7
Pilling-Weck, medium-large clip size, 10mm, rotatable take apart
Insert only, Pilling-Weck medium-large clip size
Insert only, Ethicon, small clip size
Ethicon, small clip size, 10mm, rotatable take apart
Medicine Products: